<DOC>
	<DOCNO>NCT02821312</DOCNO>
	<brief_summary>This study Phase I , Randomised , Double-Blind , Placebo-Controlled , Dose-Escalation Study Evaluate Safety , Tolerability Pharmacokinetics After Single Multiple Oral Administration DA-8010 Healthy Subjects .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability Pharmacokinetics DA-8010 Healthy Subjects</brief_title>
	<detailed_description>This study randomise , double-blind , placebo-controlled , dose-escalation , single multiple oral dose study conduct 2 part . In Part A , subject participate 1 treatment period reside Clinical Research Unit ( CRU ) Day -1 ( day dose ) Day 3 ( 48 hour postdose ) , except Group A4 , subject participate 2 treatment period separate minimum 13 day evaluate effect food . In Part B , subject participate 1 treatment period reside CRU Day -1 ( 1 day dose ) morning Day 9 ( 48 hour final dose Day 7 ) .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>BMI 18.0 32.0 kg/m2 Subjects give write informed consent participate study abide study restriction Subjects agree use method acceptable contraception Female subject childbearing potential agree use highly effective method birth control Consume 28 21 unit alcohol per week male female , respective Subjects use nicotinecontaining product ( include cigarette ) , within 3 month prior first dose administration Subjects use , intend use product like nonprescribed systemic topical medication , herbal remedy , vitamin/mineral supplement , within 7 day first dose administration Systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg Diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg Pulse rate &lt; 45 bpm &gt; 100 bpm Positive urine drug abuse screen screen first admission Positive alcohol breath test screen first admission Positive cotinine test screen first admission Abnormality 12lead ECG screening , admission predose Day 1 Subjects pregnant , breastfeeding , lactate Subjects still participate another clinical study ( e.g . attend followup visit ) participate clinical study involve administration investigational drug past 3 month prior first dose administration Subjects significant history drug allergy , determine Investigator Aspartate aminotransferase and/or Alanine aminotransferase ≥ 1.5 × upper limit normal ( ULN ) total bilirubin &gt; ULN screen admission Subjects carrier HBsAg hepatitis C antibody , serum hepatitis positive result test HIV antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>